Robert L Penn, MD | |
1501 Kings Hwy, Department Of Medicine, Infectious Disease, Shreveport, LA 71103 | |
(318) 675-7737 | |
(318) 675-5666 |
Full Name | Robert L Penn |
---|---|
Gender | Male |
Speciality | Internal Medicine - Infectious Disease |
Location | 1501 Kings Hwy, Shreveport, Louisiana |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1821246737 | NPI | - | NPPES |
1195332 | Medicaid | LA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RI0200X | Internal Medicine - Infectious Disease | 04670R (Louisiana) | Primary |
Mailing Address | Practice Location Address |
---|---|
Robert L Penn, MD 1501 Kings Hwy, Department Of Medicine, Infectious Disease, Shreveport, LA 71103 Ph: (318) 675-7737 | Robert L Penn, MD 1501 Kings Hwy, Department Of Medicine, Infectious Disease, Shreveport, LA 71103 Ph: (318) 675-7737 |
News Archive
After a decade of research, Zapne LLC has released its signature acne treatment, Zapne, an all-natural product to treat acne without the harsh side effects of many current regimens. Zapne offers four key advantages over most acne treatments: The treatment system is formulated from natural, non-synthetic ingredients, produces no material side effects, requires only a single 15-minute weekly application, and produces visible results quickly, in some cases after only one or a few applications.
A large study of hand and shoulder surgeries performed at a freestanding, outpatient center found few complications-0.2 percent in nearly 29,000 patients over an 11-year period. The study appears in the new issue of the Journal of Bone and Joint Surgery.
Contrary to popular belief, birth control pills account for less than 1 percent of the estrogens found in the nation's drinking water supplies, scientists have concluded in an analysis of studies published on the topic.
Shire plc, the global specialty biopharmaceutical company, today presented positive data from a Phase III clinical trial (TKT-034) designed to evaluate the safety of switching to VPRIV (velaglucerase alfa for injection), from imiglucerase, as well as an interim analysis of safety data from an ongoing multicenter open-label treatment protocol (HGT-GCB-058) implemented to provide VPRIV to patients affected by the continuing shortage of imiglucerase.
› Verified 6 days ago
Mansi Shah, D.O. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1455 E Bert Koun Loop, #210, Shreveport, LA 71105 Phone: 318-798-4515 Fax: 318-798-4530 | |
Pratik Agrawal, Infectious Disease Medicare: Medicare Enrolled Practice Location: 1541 Kings Hwy, Shreveport, LA 71103 Phone: 318-626-0000 | |
Dr. Bader Alotaibi, M.D. Infectious Disease Medicare: Medicare Enrolled Practice Location: 2727 Hearne Ave Ste 301, Shreveport, LA 71103 Phone: 318-631-6400 | |
Paul A Rushing, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1455 E Bert Kouns Loop, Shreveport, LA 71105 Phone: 318-798-4488 Fax: 318-798-4420 | |
Sanjay Jain, Infectious Disease Medicare: Medicare Enrolled Practice Location: 510 E Stoner Ave, Primary Care (110), Shreveport, LA 71101 Phone: 318-221-8411 | |
Steven R Bailey, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1541 Kings Hwy, Shreveport, LA 71103 Phone: 318-626-0000 | |
Venkateswara K Rao, M.D., Infectious Disease Medicare: Medicare Enrolled Practice Location: 1501 Kings Hwy, Department Of Medicine, Shreveport, LA 71103 Phone: 318-675-5000 |